STAGE IV RENAL CELL CANCER AJCC V8
Clinical trials for STAGE IV RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the drugs for 12 weeks, then have surgery to remove the tumor. The …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New combo therapy targets hard-to-treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in 65 people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and check side effects. Researchers hope this combination can he…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New combo therapy shows promise in advanced kidney cancer trial
Disease control OngoingThis phase III trial compares the usual immunotherapy (nivolumab and ipilimumab followed by nivolumab alone) to the same treatment plus an additional drug called cabozantinib in 1,175 patients with advanced kidney cancer that has spread. The goal is to see if adding cabozantinib …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:27 UTC
-
Could a superfruit boost immunotherapy for kidney cancer?
Disease control OngoingThis early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and effective for people with advanced kidney cancer that has spread. About 31 participants will receive the combination to see if it improves gu…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib works better than cabozantinib alone for people with advanced papillary kidney cancer that has spread. About 200 participants will receive either the combination or cabozantinib …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New drug targets cancers missing key gene
Disease control OngoingThis study tests a drug called adavosertib in adults with advanced solid tumors that lack a gene called SETD2. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them from getting worse.
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New immune cell therapy trial for advanced cancers withdrawn before start
Disease control TerminatedThis early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancers, or melanoma. The treatment uses a patient's own immune cells taken from their tumor, grown in a lab, and then given back to…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
Can a phone app ease the fear of advanced kidney cancer?
Symptom relief OngoingThis study looks at whether using a mindfulness app is practical and helpful for people with metastatic kidney cancer. About 21 participants will use the app to practice mindfulness and complete surveys about their anxiety, depression, fatigue, and quality of life. The goal is to…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated May 01, 2026 15:28 UTC